Overview
Sensus Healthcare Q3 2025 revenue of $6.9 mln beats analyst expectations
Net loss for Q3 2025 was $0.9 mln, reflecting operational challenges
Adjusted EBITDA for Q3 2025 missed analyst estimates
Outlook
Company sees strong interest internationally following MDSAP certification
CMS coding expected to strengthen SRT adoption and reimbursement certainty
Result Drivers
INCREASED TREATMENT VOLUME - FDA treatment volumes rose 20% over the second quarter, reflecting growing adoption
INTERNATIONAL EXPANSION - Shipped 16 SRT systems, including three to China, and preparing for broader expansion
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $6.88 mln | $6.25 mln (5 Analysts) |
Q3 Net Income | -$943,000 | ||
Q3 Adjusted EBITDA | Miss | -$2.40 mln | -$485,000 (2 Analysts) |
Q3 Basic EPS | -$0.06 | ||
Q3 Operating Expenses | $5.28 mln | ||
Q3 Pretax Profit | -$2.41 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Sensus Healthcare Inc is $8.00, about 53.9% above its November 5 closing price of $3.69
The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 17 three months ago
Press Release: ID:nBw4Cy8Dqa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)